Maegim한국어

한미약품

128940KOSPISector: Pharma & Biotech
₩372,500▲ 0.13%Market cap ₩4.77TAs of Jul 21, 2026 close · updated once daily
B
Grade B59.1 ptsTop 36% of 2,523 stocks
Financial strength
69.0
Growth momentum
57.8
Price attractiveness
48.8

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

69.0
How much debt does it carry relative to equity?
Debt-to-equity ratio
50.2%
✓ Above median · Top 48.2% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
147.7%
✗ Below median · Top 58.7% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
16.7%
✓ Above median · Top 9.7% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
13.6%
✓ Above median · Top 7.5% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

57.8
How much did revenue grow in a year?
Revenue growth (YoY)
3.5%
✗ Below median · Top 59.6% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
5.1%
✓ Above median · Top 49.2% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
19.2%
✓ Above median · Top 37.3% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
63.1%
✓ Above median · Top 22.8% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

48.8
Is the price expensive relative to earnings?
P/E (price-to-earnings)
28.1x
✓ Above median · Top 29.9% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
3.82x
✗ Below median · Top 72.6% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15